EP 2 654 789 B1 relates to antibodies against human CD39 for inhibiting the immunosuppressive effects of a CD39-expressing cancerous cell.
Brief outline of the case
The patent was revoked and the proprietor appealed.
During the appeal the patent has lapsed with effect for all the designated Contracting States.